A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers.

Trial Profile

A 6-Month, Phase 3, Randomized, Double-Blind, Parallel-Group, Controlled, Multi-Center Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Developing Aspirin-Associated Ulcers.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Aspirin/omeprazole (Primary) ; Aspirin
  • Indications Cardiovascular disorders
  • Focus Adverse reactions; Registrational
  • Sponsors POZEN
  • Most Recent Events

    • 09 Jan 2017 According to an Aralez Pharmaceuticals Inc. media release, the company has submitted a Marketing Authorization Application (MAA) to the EMA for PA10040 (YOSPRALA) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers based on results from three trials (CTPs 700036117, 700048158 and 700225598)
    • 14 Nov 2016 According to an Aralez Pharmaceuticals media release, results of pooled post hoc analysis from this and other phase III study (Profile 48158) were presented at the annual American Heart Association Scientific Sessions.
    • 14 Nov 2016 Results of pooled post hoc analysis from this and other phase III study (Profile 48158), published in an Aralez Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top